KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Edwards Lifesciences (EW) Consolidated Net Income (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Consolidated Net Income data on record, last reported at $27.0 million in Q4 2025.

  • For Q4 2025, Consolidated Net Income fell 31.3% year-over-year to $27.0 million; the TTM value through Dec 2025 reached $13.4 million, down 99.52%, while the annual FY2025 figure was $13.4 million, 99.52% down from the prior year.
  • Consolidated Net Income reached $27.0 million in Q4 2025 per EW's latest filing, up from -$2.0 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $2.7 billion in Q3 2024 and bottomed at -$7.2 million in Q1 2025.
  • Average Consolidated Net Income over 5 years is $289.7 million, with a median of $51.4 million recorded in 2023.
  • Peak YoY movement for Consolidated Net Income: skyrocketed 5447.75% in 2024, then crashed 540.0% in 2025.
  • A 5-year view of Consolidated Net Income shows it stood at $335.3 million in 2021, then plummeted by 40.2% to $200.5 million in 2022, then tumbled by 81.75% to $36.6 million in 2023, then rose by 7.38% to $39.3 million in 2024, then crashed by 31.3% to $27.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Consolidated Net Income were $27.0 million in Q4 2025, -$2.0 million in Q3 2025, and -$4.4 million in Q2 2025.